Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Understanding the role of the GPIIb/IIIa receptor in platelet aggregation provides a mechanistic basis for developing selective antagonists to treat thrombosis.
Platelets play a key role in normal hemostasis and abnormal thrombosis. A glycoprotein (GP) complex, IIb/IIIa, is found in abundance in the platelet cell membrane as a surface receptor. The complex is Ca2+ dependent, and the primary structural sequence of its components has been determined by cloning. The complex is a multifunctional receptor that binds at least 4 adhesive proteins on the activated platelet: fibrinogen, von Willebrand factor, vitronectin, and fibronectin. The mechanism by which GPIIb/IIIa binds fibrinogen and other adhesive proteins is thought to be a change in its conformation or density following platelet activation, which allows the binding to occur. This binding process serves as the common final pathway for platelet aggregation. Platelet aggregation, mediated by adhesive proteins binding to GPIIb/IIIa, is a critical component of thrombus formation and a significant factor in thrombosis in vivo, which may explain why thrombolytics fail to achieve patency in patients who have vascular complications. Binding the GPIIb/IIIa receptor with fibrinogen can be blocked by selective antagonists that are being studied in ongoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Razzuk et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: